Banned medicine (Credit-Canva)
The Union Health Ministry implemented a ban on 156 "irrational" FDC medicines, effective immediately. These medicines, including widely used antibiotics, painkillers, and multivitamins, were commonly used to treat fever, cough, and infections. The ban was imposed due to the associated health risks and lack of therapeutic justification for the ingredients in these FDCs.
FDCs or fixed-dosed combinations, also known as "cocktail drugs," are medications that combine multiple drugs in a single pill. They are designed to treat multiple symptoms or conditions simultaneously. While they offer convenience, they can pose significant risks. These risks include the possibility of overdose, adverse interactions between the drugs, and the development of antibiotic resistance. Additionally, many FDC medicines lack sufficient scientific evidence to support their safety and efficacy.
Experts have raised concerns about the use of FDC medicines. They believe that many of these combinations lack sufficient scientific evidence to support their safety and effectiveness. Additionally, the combination of multiple drugs in a single pill can increase the risk of adverse side effects and interactions with other medications.
Experts have also found that FDC medicines may not be as effective as individual drugs in treating certain conditions. It is important to note that safer and more effective alternatives are available for most of the medical conditions that FDC medicines were used to treat. One particular concern is the inclusion of antibiotics in some FDCs. Overuse of antibiotics can contribute to the development of antibiotic resistance, a major public health threat.
The use of FDC medicines can lead to adverse effects, including serious ones. Additionally, safer alternatives, tested in clinical trials, are available to treat the same medical conditions. Experts recommend prescribing drugs individually based on a patient's clinical symptoms rather than combining them in FDCs.
The ban on irrational FDC medicines by the Union Health Ministry can be seen as a positive step towards promoting rational drug use and protecting public health. The goal is to eliminate unnecessary and potentially harmful drug combinations. This is a step forward in reducing the risks associated with medication and ensure safer and more effective treatment options for patients.
Credit: iStock
France is reporting a rise in COVID-19 cases as the government prepares to launch its autumn COVID and flu vaccination campaign on October 13. The increase comes as neighboring UK is also reporting higher COVID activity and hospitalizations.
Data from the Réseau Sentinelles and other networks monitored by Santé publique France showed an increase in COVID-19 infections during the week of September 21-27, The Connexion reported.
The estimated number of people with COVID-19 who consulted GPs for acute respiratory infections rose to 13 per 100,000, up from nine the previous week. This translates to around 8,806 new cases, compared with about 6,000 the previous week.
The figures cover only people who consulted a GP, so the actual number of infections could be higher.
Overall, acute respiratory infections reported by GPs rose from 103 to 151 cases per 100,000 people. Rhinoviruses were more common, detected in 40% of samples, compared with 10% for COVID.
Emergency visits for suspected COVID among people aged 15 and older also increased by 22%, or 114 visits. However, hospital admissions following emergency visits remained stable and overall COVID activity remained at a low level.
"As always, it's not the patient's interest that counts, but that of the system," said Jérôme Marty, a GP in southern France, according to Franceinfo. Marty said he had been seeing a steady stream of COVID patients in recent weeks.
Also read:‘American Covid’ Strain Drives 50% Surge in UK Hospital Admissions: XFG Symptoms to Know
The French government has rejected demands from a doctors’ union to bring forward the vaccination campaign.
Marty, who is also president of the UFML doctors’ union, said he was “dismayed” by the decision to start the campaign on October 13.
"There is no public health campaign; people are not reminded to wear a mask when they have symptoms... We are lagging!" he said.
The office of Health Minister Stéphanie Rist said that “indicators do not show a situation justifying the early launch of the campaign.”
Meanwhile, pharmacy groups have raised concerns about vaccine administration supplies. In an open letter to the minister, they warned that multi-dose vaccine vials require suitable syringes and needles, which pharmacists must now purchase themselves.
The groups called for sufficient supplies and financial coverage and urged greater use of pre-filled syringes in future campaigns.
Read More: COVID-19 May Raise Risk of 6 Allergic Conditions, Study Finds
For autumn 2026, France will use the monovalent Comirnaty XFG vaccine.
COVID vaccination is particularly recommended for people at higher risk of severe disease, including those aged 65 and over, pregnant women, people with weakened immune systems and those with certain chronic conditions.
The 30-microgram dose is for people aged 12 and older, while the 10-microgram dose is for children aged 6 months to 11 years.
In England, COVID activity increased in the week to September 20. Hospital PCR positivity rose from 5.9% to 7.0%, while hospital admissions increased from 0.81 to 1.20 per 100,000 people. Overall activity remained low.
In the US, CDC data from September 29 showed cases rising in some states while falling or remaining stable in others.
XFG is a recombinant SARS-CoV-2 variant formed from Omicron subvariants LF.7 and LP.8.1.2. The WHO records the earliest documented XFG sample on January 27, 2025, and designated it a variant under monitoring in June 2025.
The variant has since been detected in multiple countries and remains among the SARS-CoV-2 variants being monitored by WHO.
What Are the Symptoms of XFG?
COVID symptoms can vary between individuals. Reported symptoms associated with the current circulation of XFG include:
Credit: X
Veteran Indian actor Nana Patekar died at the age of 75 at his residence in Goa on Thursday, October 8 at 5:20 am after suffering a cardiac arrest.
His son Malhar Patekar confirmed the death. Doctors attempted CPR for around 45 minutes, but the actor could not be revived. Dr. Shekhar Salkar, Chief of Oncology Department, Manipal Hospital, said that a medico-legal case (MLC) has been registered, and a post-mortem will be conducted. Patekar's cause of death will be ascertained after the post-mortem.
Patekar's death has once again sparked attention to cardiac arrest, a medical emergency that can strike suddenly. But cardiac arrest is not the same as a heart attack, despite the two terms often being used interchangeably.
Cardiac arrest occurs when the heart suddenly stops pumping blood effectively to the brain and other vital organs. It is usually caused by an electrical malfunction that triggers a dangerous abnormal heart rhythm, known as an arrhythmia.
Within seconds, a person may collapse, become unconscious and stop breathing normally. Without immediate treatment, cardiac arrest can become fatal within minutes.
Unlike some medical conditions that produce warning symptoms before striking, cardiac arrest can happen abruptly, making rapid intervention crucial.
Also read: When Do You Need A Heart Check-up?
Basically, a heart attack is primarily a blood-flow problem, while cardiac arrest is an electrical issue. During a heart attack, a blocked artery prevents oxygen-rich blood from reaching part of the heart muscle.
The heart usually continues beating. During cardiac arrest, however, the heart's electrical system malfunctions and the heart stops pumping blood.
Dr. Vanita Arora, Clinical Lead – Cardiac Electrophysiology, Senior Consultant - Interventional Cardiologist & Cardiac Electrophysiologist, Indraprastha Apollo Hospital, New Delhi told HealthandMe, "Cardiac arrest and heart attack are totally different things. Cardiac arrest is an electrical problem in the heart, where the heart goes into an abnormal rhythm and stops contracting effectively."
She added, "A heart attack, on the other hand, is a plumbing problem, where there is choking or blockage of the arteries that supply blood to the heart. In cardiac arrest, there is a problem with the electrical conduction system of the heart, whereas in a heart attack there is a blockage in the blood supply. Both are different conditions and have to be managed in totally different ways."
The two conditions are connected because a heart attack can sometimes trigger a cardiac arrest, although most heart attacks do not result in cardiac arrest.
Also read: Innovations in Structural Heart Care: The Shift Towards Minimally Invasive Therapies
Cardiac arrest requires immediate medical intervention. Cardiopulmonary resuscitation, or CPR, helps maintain blood flow to vital organs until the heart can be restarted.
An automated external defibrillator, or AED, can analyse the heart's rhythm and deliver an electrical shock to restore a normal rhythm.
Dr. Arora elaborates on the importance of starting CPR as soon as possible to save one's life.
She said, "CPR is extremely important and should be started immediately when sudden cardiac arrest is recognized. It is the best chance that a person has for survival, but it is never 100% certain that CPR will revive the patient. Even if CPR is started in time and continued for 45 minutes, the patient may not be revived."
She added, "The important thing is that CPR should be started as early as possible because the first few minutes are critical. A delay in starting resuscitation measures can further reduce the chances of revival."
The American Heart Association says immediate CPR can double or triple the chance of survival from an out-of-hospital cardiac arrest.
If someone collapses suddenly and is unresponsive with no normal breathing, emergency medical services should be called immediately to start CPR.
The risk of cardiovascular disease generally increases with age. Conditions like coronary artery disease, high blood pressure and abnormalities of heart rhythm can contribute to serious cardiac events. Smoking is one of the major risk factors.
There were no recent reports of Patekar's ill health. But in the past, he has spoken extensively about his heavy smoking history.
According to the Indian Express, Patekar opened about smoking around 60 cigarettes a day. He said he smoked heavily until his mid-50s and eventually quit after a personal incident made him reconsider the habit. He later said he had remained smoke-free for around 20 years.
Cardiac arrest is not exclusively a disease of older adults. It can occur in people with known heart disease as well as those who may not have previously been diagnosed with a heart condition.
Credit: AI
Days after the death of Darya Shipilova, a 28-year-old laboratory technician in Irkutsk's Anti-Plague Research Institute, sparked global headlines about a possible pneumonic plague outbreak, reports of a suspected second case instilled concern in global health bodies and citizens.
Russia responded to the reports of the second plague case in Siberia, while the World Health Organization (WHO) says it still lacks enough information to determine what caused the death of the laboratory worker.
Initial reports suggested she could have contracted pneumonic plague following a possible laboratory exposure, although Russian authorities have not confirmed that diagnosis.
Also read: Second Plague Death Reported As Russia Denies Outbreak
Local media reported the second death after Baikalsk authorities issued a Telegram warning on October 3 about “unofficial information” of a confirmed plague case in Shelekhov, The Daily Mail reported.
“Due to unofficial information about a confirmed case of plague in a person in the city of Shelekhov, we ask you to limit visits to Shelekhov and nearby settlements until the circumstances surrounding this threat are clarified,” the administration said.
The post was deleted about two hours later, according to local media Lyudi Baikala. There is no official confirmation that the person had plague or died from Yersinia pestis.
Russia's public health watchdog, Rospotrebnadzor, however, has maintained that Shipilova died from pneumonia of unknown or undetermined origin, rather than plague.
The agency said nearly 5,000 laboratory tests conducted among people connected to the incident had found no dangerous pathogens. More than 90% of the people who were placed under medical observation had completed monitoring.
Rospotrebnadzor also said Shipilova had been vaccinated and had immunity against the dangerous infections she worked with. It said there was no epidemic risk in the region.
The Kremlin has also rejected reports of a second suspected case. Kremlin spokesman Dmitry Peskov said the majority of media reports surrounding the incident were false and urged people to rely on official statements from Rospotrebnadzor.
According to Reuters, “There is a great deal of media coverage, and the vast majority of what the media are reporting about this situation is false information,” Peskov said.
Also read: Russia Tells WHO No Plague Cases In Irkutsk, But Lab Worker's Death Remains Unexplained
Despite Russia's reassurances, the WHO says important questions about the lab worker's death still remain unanswered. WHO Director-General Tedros Adhanom Ghebreyesus said the organisation has requested details of the laboratory testing carried out on Shipilova and her contacts, the reasons behind the public-health measures and the current health status of those monitored.
The WHO has also asked Russia to verify reports that a second employee developed pneumonia of undetermined cause.
“As we don’t yet have the full picture of this event, we are not able to conduct a full risk assessment,” Tedros said. He stressed that timely, complete and transparent information is necessary to establish what happened and assess any potential public-health risk.
Maria Van Kerkhove, WHO director of epidemic and pandemic management, said the agency does not yet know the causative agent behind Shipilova's death.
“Right now, we don't know the causative agent of how this woman died. And that's really what we want to better understand,” she said.
There's also uncertainty which has prompted questions in the US about whether the incident could involve a biological weapon.
US President Donald Trump was asked on October 7 whether he believed the Russian lab worker's death was linked to a bioweapon, US President Donald Trump said: “We don't think so. We're going to find out soon enough, but we don't think so.”
He also said his administration was in “very deep discussions” about the incident and that he had a call with Russian President Vladimir Putin scheduled.
US officials, meanwhile, have continued monitoring the situation. CDC Director Erica Schwartz said the agency was prepared to monitor and screen travellers.
Secretary of State Marco Rubio said Washington was monitoring reports of possible plague but said they were not a “cause for alarm”. “There’s very limited travel between the US and Russia, obviously, but like anything else, something like that gets out, it could quickly spread,” Rubio said.
“So we're watching and monitoring it closely. I don't think it's cause for alarm – but it is cause for focus and a cause to just keep an eye on it. And we're doing that.”
Meanwhile, neighboring countries including Mongolia, Kyrgyzstan and Uzbekistan have reportedly tightened border health measures.
© $2026 Times Horizon Private Limited